- Home
- CARM vs UNCY Comparison
CARM vs UNCY Comparison
Compare CARM & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CARM
- UNCY
- Stock Information
- Founded
- CARM 2016
- UNCY 2016
- Country
- CARM United States
- UNCY United States
- Employees
- CARM N/A
- UNCY N/A
- Industry
- CARM Biotechnology: Pharmaceutical Preparations
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- CARM Health Care
- UNCY Health Care
- Exchange
- CARM Nasdaq
- UNCY Nasdaq
- Market Cap
- CARM 35.5M
- UNCY 31.9M
- IPO Year
- CARM N/A
- UNCY 2021
- Fundamental
- Price
- CARM $0.47
- UNCY $0.66
- Analyst Decision
- CARM Hold
- UNCY Strong Buy
- Analyst Count
- CARM 5
- UNCY 4
- Target Price
- CARM $4.57
- UNCY $5.50
- AVG Volume (30 Days)
- CARM 329.1K
- UNCY 1.4M
- Earning Date
- CARM 11-07-2024
- UNCY 11-13-2024
- Dividend Yield
- CARM N/A
- UNCY N/A
- EPS Growth
- CARM N/A
- UNCY N/A
- EPS
- CARM N/A
- UNCY N/A
- Revenue
- CARM $20,268,000.00
- UNCY N/A
- Revenue This Year
- CARM $46.34
- UNCY N/A
- Revenue Next Year
- CARM N/A
- UNCY N/A
- P/E Ratio
- CARM N/A
- UNCY N/A
- Revenue Growth
- CARM 41.13
- UNCY N/A
- 52 Week Low
- CARM $0.38
- UNCY $0.20
- 52 Week High
- CARM $3.16
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- CARM 21.83
- UNCY 55.55
- Support Level
- CARM $0.38
- UNCY $0.62
- Resistance Level
- CARM $0.82
- UNCY $0.87
- Average True Range (ATR)
- CARM 0.06
- UNCY 0.07
- MACD
- CARM -0.03
- UNCY -0.01
- Stochastic Oscillator
- CARM 18.22
- UNCY 25.00
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.